p38 MAPK

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1076 SB203580 <1 mg/mL 43 mg/mL <1 mg/mL
S1574 Doramapimod (BIRB 796) <1 mg/mL 100 mg/mL 100 mg/mL
S1077 SB202190 (FHPI) <1 mg/mL 66 mg/mL 12 mg/mL
S1494 Ralimetinib (LY2228820) 100 mg/mL 4 mg/mL 3 mg/mL
S6005 VX-702 <1 mg/mL 81 mg/mL <1 mg/mL
S8706 UM-164 <1 mg/mL 100 mg/mL <1 mg/mL
S2726 PH-797804 <1 mg/mL 96 mg/mL 7 mg/mL
S1458 VX-745 <1 mg/mL 15 mg/mL <1 mg/mL
S2928 TAK-715 <1 mg/mL 80 mg/mL 16 mg/mL
S8125 Pamapimod (R-1503, Ro4402257) <1 mg/mL 81 mg/mL 28 mg/mL
S7741 SB239063 <1 mg/mL 60 mg/mL 7 mg/mL
S7214 Skepinone-L <1 mg/mL 85 mg/mL 85 mg/mL
S7215 Losmapimod (GW856553X) <1 mg/mL 76 mg/mL 41 mg/mL
S2266 Asiatic Acid <1 mg/mL 97 mg/mL <1 mg/mL
S8124 BMS-582949 <1 mg/mL 81 mg/mL <1 mg/mL
S7799 Pexmetinib (ARRY-614) <1 mg/mL 100 mg/mL 100 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations


SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.


Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.


SB202190 (FHPI)

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.


Ralimetinib (LY2228820)

Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.



VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.



UM-164 is a highly potent, dual c-Src/p38inhibitor of c-Src with a binding constant Kd of 2.7 nM for c-Src and inhibits both p38α and p38β.



PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.



VX-745 is a potent and selective inhibitor of p38α with IC50 of 10 nM, 22-fold greater selectivity versus p38β and no inhibition to p38γ.



TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.


Pamapimod (R-1503, Ro4402257)

Pamapimod (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase. It inhibits p38α and p38β enzymatic activity with IC50 values of 0.014±0.002 and 0.48± 0.04 microM, respectively with no activity against p38delta or p38gamma isoforms.



SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.



Skepinone-L is a selective p38α-MAPK inhibitor with IC50 of 5 nM.


Losmapimod (GW856553X)

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.


Asiatic Acid

Asiatic acid is the aglycone of asiaticoside isolated from the plant Centella asiatica, commonly used in wound healing.



BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM,inhibiting both p38 kinase activity and activation of p38.


Pexmetinib (ARRY-614)

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

Tags: p38 MAPK activation | p38 MAPK pathway | p38 protein kinase | p38 MAPK signaling | p38 MAP Kinase pathway | p38 MAPK activity | p38 MAPK phosphorylation | p38 MAPK apoptosis | p38 MAPK signaling pathway | p38 MAPK cancer | p38 kinase assay | p38 inhibitors clinical trials | p38 MAPK assay | p38 MAPK inhibitors clinical trials | p38 MAPK inhibitor review